These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Desferrioxamine-induced changes of aluminium kinetics during haemodialysis. Graf H; Stummvoll HK; Meisinger V Proc Eur Dial Transplant Assoc; 1981; 18():674-80. PubMed ID: 7329995 [TBL] [Abstract][Full Text] [Related]
23. Exacerbation of aluminium encephalopathy after treatment with desferrioxamine. Lillevang ST; Pedersen FB Nephrol Dial Transplant; 1989; 4(7):676. PubMed ID: 2510071 [No Abstract] [Full Text] [Related]
24. Recognition and management of aluminum intoxication in children. Tsuru N; Williams JL; Chan JC Int J Pediatr Nephrol; 1987; 8(3):177-86. PubMed ID: 3323095 [TBL] [Abstract][Full Text] [Related]
25. Comparison of low-dose deferoxamine versus standard-dose deferoxamine for treatment of aluminium overload among haemodialysis patients. Kan WC; Chien CC; Wu CC; Su SB; Hwang JC; Wang HY Nephrol Dial Transplant; 2010 May; 25(5):1604-8. PubMed ID: 19948879 [TBL] [Abstract][Full Text] [Related]
26. Aluminum kinetics of the REDY system: a study of the impact of deferoxamine therapy. Culpepper CP; Cummings R; Westervelt FB; Savory J; Wills MR Trans Am Soc Artif Intern Organs; 1983; 29():76-80. PubMed ID: 6673321 [No Abstract] [Full Text] [Related]
27. Reversible microcytic hypochromic anaemia in dialysis patients due to aluminium intoxication. Short AI; Winney RJ; Robson JS Proc Eur Dial Transplant Assoc; 1980; 17():226-33. PubMed ID: 7243773 [TBL] [Abstract][Full Text] [Related]
33. [Effect of deferoxamine on erythropoiesis in patients hemodialyzed for chronic renal insufficiency treated with erythropoietin]. Kalinowski M; Popławski A; Kaliszewski Z; Juzwiuk J Pol Merkur Lekarski; 1996 Oct; 1(4):232-4. PubMed ID: 9156931 [TBL] [Abstract][Full Text] [Related]
34. Toxicological aspects of aluminum poisoning in clinical nephrology. de Wolff FA Clin Nephrol; 1985; 24 Suppl 1():S9-14. PubMed ID: 3842105 [TBL] [Abstract][Full Text] [Related]
35. [Successful treatment of progressive dialysis encephalopathy. Case report]. Weiland P; Köhler M; Glatzel E Z Urol Nephrol; 1985 Jul; 78(7):387-93. PubMed ID: 4050157 [TBL] [Abstract][Full Text] [Related]
36. Indirect methods for the diagnosis of aluminum bone disease: plasma aluminum, the desferrioxamine infusion test, and serum iPTH. Nebeker HG; Andress DL; Milliner DS; Ott SM; Alfrey AC; Slatopolsky EA; Sherrard DJ; Coburn JW Kidney Int Suppl; 1986 Feb; 18():S96-9. PubMed ID: 3458006 [No Abstract] [Full Text] [Related]
37. [Aluminum poisoning caused by the phosphate binder in a non-dialysed child with chronic renal insufficiency]. Feldmann B; Färber D; Pontz BF Radiologe; 1992 Jul; 32(7):327-32. PubMed ID: 1509030 [TBL] [Abstract][Full Text] [Related]
38. Prevention and treatment of aluminum intoxication in chronic renal failure. Simon P; Allain P; Ang KS; Cam G; Mauras Y Adv Nephrol Necker Hosp; 1985; 14():439-78. PubMed ID: 3919543 [No Abstract] [Full Text] [Related]
39. Improvement of anemia with deferoxamine in hemodialysis patients with aluminum-induced bone disease. Tielemans C; Collart F; Wens R; Smeyers-Verbeeke J; van Hooff I; Dratwa M; Verbeelen D Clin Nephrol; 1985 Nov; 24(5):237-41. PubMed ID: 4075595 [TBL] [Abstract][Full Text] [Related]
40. [Desferal treatment of aluminum poisoning; effect on serum concentrations of aluminum (Al), iron (Fe) and copper (Cu)]. Günther K; Winnefeld K; Stein G; Sperschneider H; Schröter H; Fünfstück R Z Urol Nephrol; 1986 Oct; 79(10):569-76. PubMed ID: 3811645 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]